Status and phase
Conditions
Treatments
About
The purpose of this study is to investigate the efficacy and safety of intraperitoneal and intravenous nab-paclitaxel plus Camrelizumab and S-1 conversion therapy for gastric cancer with positive exfoliative cancer cells.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
None previous chemotherapy, radiotherapy and other antitumor therapy;
Age:18 to 70 years old;
Man or female (except pregnant and lactating women);
Confirmed to gastric adenocarcinoma and HER2-negative;
Proven gastric cancer of T stage was T3 and T4, and no distant metastasis was observed. The exfoliative cancer cells detection in peritoneal washes was positive;
Blood cell count has to meet the following certeria:
WBC≥3.5×109/L; ANC≥1.5×109/L; PLT≥100×109/L; HB≥90g/L;
Liver/kidney function has to meet the following certeria:
ALT and AST≤2.5×ULN TBIL<1.5×ULN; Serum creatinine ≤1.5×ULN;
Left ventricular ejection fraction (LVEF) ≥50%;
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Participants were willing to join in this study, good adherence and written informed consent.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Qun Zhao, Professor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal